KUALA LUMPUR, Sept 24 -- Nippon Express Co Ltd, acting through its subsidiary, Nippon Express (South Asia & Oceania) Pte Ltd has agreed to make an investment in India’s Future Supply Chain Solutions Limited (FSC).
The company’s board during its recently-held meeting approved the execution of a Share Subscription Agreement and Shareholder Agreement with FSC and a Share Purchase Agreement with some FSC shareholders. FSC is among India’s leading logistics service providers and a part of the Future Group, India’s largest retail group. The Nippon Express Group aims to become a logistics company with a significant presence in the global markets as laid out in the ‘Nippon Express Group Business Plan 2023 - Dynamic Growth’, beginning financial year 2018. The group’s core strategy is to focus on strengthening its India business to capitalise on the rapid growth expected in the Indian logistics market. The partnership with FSC will add complementary capabilities to Nippon Express and enable it to provide end-to-end logistics services to its customers, resulting in the growth of its Indian logistics business. -- BERNAMA
0 Comments
KUALA LUMPUR, Sept 20 -- AM Best has affirmed the Financial Strength Rating of A (excellent) and the Long-Term Issuer Credit Rating of ‘a’ of COSCO SHIPPING Captive Insurance Co Ltd (COSCO SHIPPING Captive) China.
In a statement, the global credit rating agency with an exclusive focus on the insurance industry said the outlook of these credit ratings was stable. The ratings reflect COSCO SHIPPING Captive’s balance sheet strength, which AM Best describes as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. In addition, the ratings reflect the wide range of support the company receives from its parent, China COSCO SHIPPING Corporation Limited, which AM Best perceives to benefit from strong government support. COSCO SHIPPING Captive’s risk-adjusted capitalisation remained at the strongest level last year, as measured by Best’s Capital Adequacy Ratio, and is supported by very low underwriting leverage, a prudent reinsurance programme and conservative investment portfolio. The insurance company underwrites mainly marine-related business for the group and its affiliates, as well as other risks stemming from the group’s operations including cargo, liability and commercial property. As a start-up company, COSCO SHIPPING Captive faces execution risk in achieving its business plans, although this is mitigated via conservative assumptions and regular experience reviews. More details on the company’s credit ratings at http://www.ambest.com -- BERNAMA KUALA LUMPUR, Sept 19 -- PRA Health Sciences, a full-service global contract research organisation has launched Symphony Health’s new national market measurement tool, Metys™.
Symphony Health is a wholly-owned subsidiary of PRA Health Sciences, according to a statement. Metys is the only completely integrated, all-in-one market research solution available from a contract research organisation, delivering pharmaceutical market analytics and intelligence that is both timely and comprehensive. “PRA and Symphony Health have developed a solution that quickly and efficiently brings all data to the clients’ fingertips within the Metys™ platform,” said Symphony Health president, Doug Fulling. “This offering affirms our commitment to serving our clients at the highest level with tools that will move their businesses forward, while also reinforcing our culture of innovation and excellence.” Powered by IDV®, Metys intelligently integrates prescriber, payer and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. More information at http://prahs.com and https://symphonyhealth.prahs.com. -- BERNAMA KUALA LUMPUR, Sept 17 -- The National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo® to treat chemotherapy-induced nausea and vomiting (CINV) in China.
This follows the announcement made by Helsinn Healthcare S.A., a Swiss-based pharmaceutical group and market leader in pain management, namely Mundipharma China Pharmaceutical. Under the terms of agreement, Helsinn will be responsible for supplying the drug to Mundipharma and co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities. Meanwhile, the Mundipharma China Pharmaceutical has exclusive marketing, promotion and sale rights for the oral formulation of Akynzeo® in China. Helsinn Group vice-chairman and chief executive officer, Riccardo Braglia said: “Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patients and their families, also in China. “We are also very pleased to be working in partnership with Mundipharma Pharmaceutical. Their expert knowledge and network in China will be invaluable as we begin to market Akynzeo® in this strategically important region.” -- BERNAMA KUALA LUMPUR, Sept 17 -- BitHarp Group Limited, a distinguished manufacturer of cryptocurrencies has launched two new high-performance liquid mining rigs capable of delivering excellent usage capabilities and unprecedented profit-making potential.
With high hash rate and low power consumption, the two rigs, named Lyre Miner and Harp Miner, are designed to provide ROI within just one month. Lyre Miner can fit in a limited space and offers useful features such as a touch screen interface for easy operation and monitoring while Harp Miner prioritises security and fault tolerance. The power consumption of these two rigs are 600W and 2400W, respectively. Both rigs are capable of mining Bitcoin, Litecoin, Ethereum and Dash, according to a statement. The new mining rigs are designed and configured to bring the benefits of crypto mining to common investors without much mining experience or knowledge. More information at https://www.bitharp.com. -- BERNAMA |
Archives
April 2023
|